Neutrophil-to-Lymphocyte Ratio and Ferritin as Emergency Diagnostic Tools for Identifying Hematologic Malignancy in Cytopenia
DOI:
https://doi.org/10.58600/eurjther2870Keywords:
blood cell disorders, cytopenia, diagnostic techniques and procedures, emergency service, ferritin, hospital, hematologic neoplasms, neutrophil-lymphocyte ratioAbstract
Objective: Pancytopenia, characterized by reductions in all three blood cell lines, often indicates underlying bone marrow or peripheral cell line diseases. This study evaluates the neutrophil-to-lymphocyte ratio (NLR) and ferritin levels as predictors of hematologic malignancy among cytopenic patients presenting to the emergency department.
Methods: A retrospective study was conducted on 236 cytopenic patients admitted to the Emergency Department at Ondokuz Mayıs University Hospital from January 1, 2023, to January 1, 2024. Inclusion criteria were patients aged 18 years or older with cytopenia; exclusions included patients younger than 18 years or those with known non-hematologic malignancies. Causes of cytopenia were categorized into non-hematologic malignancy (Group 1, n=182) and hematologic malignancy (Group 2, n=54). Demographic data and laboratory parameters were recorded and analyzed.
Results: Patients with hematologic malignancy had significantly lower white blood cell (WBC) and neutrophil counts, but higher lymphocyte counts and ferritin levels. The NLR was notably lower in the hematologic malignancy group compared to the non-malignancy group. ROC analysis identified NLR (AUC 0.846, cut-off ≤1.65) and ferritin (AUC 0.738, cut-off ≥407.2) as strong predictors of hematologic malignancy. Logistic regression indicated that decreasing NLR increased the likelihood of hematologic malignancy (OR 0.429, 95% CI: 0.294-0.624, p<0.001).
Conclusion: NLR and ferritin are accessible and effective predictors of hematologic malignancy in cytopenic patients in emergency settings. Further prospective studies are necessary to validate these findings against advanced diagnostic tests.
References
[1] Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK (2018) Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Rev. 32(5):361–367. https://doi.org/10.1016/j.blre.2018.03.001
[2] Devitt KA, Lunde JH, Lewis MR (2014) New onset pancytopenia in adults: a review of underlying pathologies and their associated clinical and laboratory findings. Leuk Lymphoma. 55(5):1099-105. https://doi.org/10.3109/10428194.2013.821703
[3] Weinzierl EP, Arber DA (2013) The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. Am J Clin Pathol. 139(1):9-29. https://doi.org/10.1309/AJCP50AEEYGREWUZ
[4] Leoni S, Ferraresi M, Motta I, Hu C, Fracanzani AL, Barcellini W, Fattizzo B (2024) Deciphering cytopenias in internal medicine: a single-center observational study. Intern Emerg Med. 19(3):661-668. https://doi.org/10.1007/s11739-023-03517-z
[5] Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell. 19;140(6):883-99. https://doi.org/10.1016/j.cell.2010.01.025
[6] Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L (2010) The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer. 20(6):1052-1057. https://doi.org/10.1111/IGC.0b013e3181e64bb1
[7] McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 39(5):534-540. https://doi.org/10.1016/j.ctrv.2012.08.003
[8] Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 57(5):1013-1020. https://doi.org/10.1016/j.jhep.2012.06.022
[9] Proctor MJ, Horgan PG, Talwar D, Fletcher CD, Morrison DS, McMillan DC (2013) Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer. 15;119(12):2325-2332. https://doi.org/10.1002/cncr.28018
[10] Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Kim JE, Kim CW, Huh J (2012) Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol. 138(6):846-854. https://doi.org/10.1309/AJCPO46GFKGNXCBR
[11] Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 29;106(6):dju124. https://doi.org/10.1093/jnci/dju124
[12] van Zeventer IA, de Graaf AO, van der Klauw MM, Vellenga E, van der Reijden BA, Schuringa JJ, Diepstra A, Malcovati L, Jansen JH, Huls G (2021) Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. Blood Adv. 14;5(17):3266-3278. https://doi.org/10.1182/bloodadvances.2021004355
[13] Mushtaq MU, Chaudhary SG, Murthy GSG, Hall AC, Atallah EL, Mattison RJ (2018) Prognostic significance of neutrophil-to-lymphocyte ratio in relapsed/refractory acute myeloid leukemia. Blood. 132(Supp1):5246. https://doi.org/10.1182/blood-2018-99-112204
[14] Zeng Q, Liu Z, Li Q, Liu T (2018) Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: A meta-analysis. Medicine (Baltimore). 97(41):e12678. https://doi.org/10.1097/MD.0000000000012678
[15] Mu S, Ai L, Fan F, Sun C, Hu Y (2018) Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther. 23(11):499-507. https://doi.org/10.2147/OTT.S153146
[16] Lee GW, Park SW, Go SI, Kim HG, Kim MK, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Kim H, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Yi HG, Moon JH, Choi CW, Kim SH, Kim BS, Park MR, Shim H, Song MK, Kim Y, Kim K (2018) The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Acta Haematol. 140(3):146-156. https://doi.org/10.1159/000490488
[17] Kelkitli E, Atay H, Cilingir F, Güler N, Terzi Y, Ozatlı D, Turgut M (2014) Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol. 93(5):841-846. https://doi.org/10.1007/s00277-013-1978-8
[18] Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F (2018) Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol. 97(6):1009-1018. https://doi.org/10.1007/s00277-018-3276-y
[19] Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y (2018) Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 22(18):119. https://doi.org/10.1186/s12935-018-0609-9
[20] Yu S, Li Q, Xiang K, Hua Y, Zhao X (2023) Prevalence and severity of thrombocytopenia in patients with hyperferritinemia. Hematology. 28(1):2186047. https://doi.org/10.1080/16078454.2023.2186047
[21] Kernan KF, Carcillo JA (2017) Hyperferritinemia and inflammation. Int Immunol. 29(9):401-409. https://doi.org/10.1093/intimm/dxx031
[22] Sackett K, Cunderlik M, Sahni N, Killeen AA, Olson AP (2016) Extreme Hyperferritinemia: Causes and Impact on Diagnostic Reasoning. Am J Clin Pathol. 145(5):646-650. https://doi.org/10.1093/ajcp/aqw053
[23] Schaffner M, Rosenstein L, Ballas Z, Suneja M (2017) Significance of Hyperferritinemia in Hospitalized Adults. Am J Med Sci. 354(2):152-158. https://doi.org/10.1016/j.amjms.2017.04.016
[24] Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW; British Society for Haematology (2018) Investigation and management of a raised serum ferritin. Br J Haematol. 181(3):331-340. https://doi.org/10.1111/bjh.15166
Downloads
Published
How to Cite
License
Copyright (c) 2026 Mustafa Selçuk Ayar, Alper Yaşar, Fatih Çalışkan, Engin Kelkitli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
